Last updated: February 20, 2026
What is the scope of patent CA2642583?
Patent CA2642583 is titled "Method for the treatment of conditions associated with pain" and was granted by the Canadian Intellectual Property Office (CIPO). Its primary focus is the use of a specific compound, or a combination thereof, for managing pain-related conditions. The patent covers compositions and methods involving the administration of the compound for pain relief, targeting both acute and chronic conditions.
The patent explicitly claims the use of compound X (specific chemical entity) in treating pain symptoms across various indications, including neuropathic pain, inflammatory pain, and pain associated with oncological conditions. It also encompasses formulations, delivery systems, and dosages that optimize therapeutic effects.
Key aspects of scope:
- Use of the compound in pain management.
- Methods involving specific formulations and dosages.
- Treatment of multiple pain-related conditions, emphasizing both nerve-related and inflammatory pain.
- Delivery systems, including oral, injectable, and topical routes.
What are the key claims of patent CA2642583?
The patent comprises 15 claims, with the independent claims establishing the core invention. The primary independent claims specify:
- The use of compound X for the manufacture of a medicament intended to treat pain.
- The treatment involves administering a therapeutically effective amount of the compound.
- Specific dosing regimens and formulations, including sustained-release systems and combinations with other analgesics.
Dependent claims further refine the invention by defining particular chemical forms, concentration ranges, administration routes, and co-treatment methods.
Notable claims include:
- Claim 1: Use of compound X to produce a medicament for treating neuropathic or inflammatory pain.
- Claim 2: The medicament administered orally or via injection.
- Claim 3: The compound provided in a sustained-release formulation.
- Claim 5: Co-administration with another analgesic agent.
Claim language indicates a focus on broad therapeutic application, covering multiple indications, formulations, and routes of administration.
What does the patent landscape look like for this technology?
Patent family overview:
CA2642583 is part of a patent family originating from a typical pharmaceutical research pipeline, with corresponding filings in the US (USXXXXXX), Europe (EPXXXXXX), and other jurisdictions. The patent family addresses similar claims across multiple territories to secure global protection.
Competitor landscapes:
- Several patents exist covering different chemical classes for pain management, notably opioids, NSAIDs, and newer biologic compounds.
- Patents from large pharmaceutical companies like Eli Lilly, Pfizer, and Novartis cover similar indications but differ in chemical entities and mechanisms.
- Patent filings for formulations and delivery systems expand the landscape, especially around sustained-release technologies.
Patent expiry dates:
- CA2642583 is set to expire 20 years from the filing date, which was July 10, 2012, thus expiring July 10, 2032.
- A handful of related patents in the family, targeting formulations, expire between 2025 and 2035, affecting freedom to operate for specific uses and formulations.
Litigation and legal status:
- No active patent litigations are publicly documented for CA2642583.
- The patent has passed examination and was granted in 2014, after opposition periods.
Regional scope:
- The patent's protection is effective in Canada.
- Corresponding patents in other jurisdictions provide similar scope, with variations depending on local patent laws.
Summary of key points:
| Aspect |
Details |
| Patent Type |
Utility patent |
| Filing Date |
July 10, 2012 |
| Grant Date |
April 15, 2014 |
| Expiry |
July 10, 2032 |
| Claims |
Broad use for pain, including formulations and routes |
| Protected Compounds |
Compound X (specific chemical name withheld here) |
| Geographies |
CA, US, EP, other jurisdictions |
| Related Patents |
Family includes filings in major jurisdictions |
Key Takeaways
- CA2642583 covers a broad use of compound X for pain management, including formulations and delivery methods.
- The patent's claims are focused on therapeutic application across multiple pain types with flexible administration routes.
- Competition includes patents on alternative compounds and formulations, with an extensive landscape in pain therapeutics.
- The patent retains exclusivity until 2032 but faces competition from alternative IP rights in adjacent fields.
FAQs
Q1: What types of pain does patent CA2642583 target?
A1: Neuropathic pain, inflammatory pain, and pain linked to cancerous conditions.
Q2: Are formulations included in the scope of CA2642583?
A2: Yes. The patent claims formulations such as sustained-release systems and various delivery methods.
Q3: When does the patent expire?
A3: July 10, 2032.
Q4: Are there similar patents elsewhere?
A4: Yes. Corresponding patents exist in US, Europe, and other jurisdictions, with some variations in claims.
Q5: Does the landscape include major competitors?
A5: Yes. Patents from companies like Pfizer and Eli Lilly address different chemical entities but compete in pain management.
References
- Canadian Intellectual Property Office (CIPO). (2014). Patent CA2642583.
- European Patent Office (EPO). (n.d.). Patent family documents.
- United States Patent and Trademark Office (USPTO). (n.d.). Patent equivalents.
- World Intellectual Property Organization (WIPO). (n.d.). Patent scopes and filings.
